TomegaVax Overview
- Year Founded
-
2011
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
TomegaVax General Information
Description
Developer of an immunotherapy vaccine technology platform designed for treating chronic and recurring viral infections. The company's platform provides continuous low-level antigen presentation to maintain an active T-cell-mediated immune shield that brings previously intractable disease targets into the grasp of immune-based therapy, enabling patients to get vaccines and immunotherapies for chronic and recurring viral infections.
Contact Information
Website
www.tomegavax.comCorporate Office
- 4640 SouthWest Macadam Avenue
- Suite 130A
- Portland, OR 97239
- United States
Corporate Office
- 4640 SouthWest Macadam Avenue
- Suite 130A
- Portland, OR 97239
- United States
TomegaVax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 19-Oct-2020 | Completed | Out of Business | |||
| 4. Grant | 01-Jan-2018 | Completed | Generating Revenue | |||
| 3. Grant | 03-Mar-2017 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series A) | 01-Jan-2017 | Completed | Generating Revenue | |||
| 1. Merger/Acquisition | 01-Jan-2016 | Completed | Generating Revenue |
TomegaVax FAQs
-
When was TomegaVax founded?
TomegaVax was founded in 2011.
-
Where is TomegaVax headquartered?
TomegaVax is headquartered in Portland, OR.
-
What industry is TomegaVax in?
TomegaVax’s primary industry is Drug Discovery.
-
Is TomegaVax a private or public company?
TomegaVax is a Private company.
-
What is TomegaVax’s current revenue?
The current revenue for TomegaVax is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process